JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report

Acta Haematol. 2013;129(1):23-5. doi: 10.1159/000342100. Epub 2012 Sep 19.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Alleles
  • Antineoplastic Agents / therapeutic use
  • Bone Marrow Neoplasms / diagnosis
  • Bone Marrow Neoplasms / drug therapy
  • Drug Therapy, Combination
  • Etoposide / therapeutic use
  • Humans
  • Janus Kinase 2 / genetics*
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy
  • Male
  • Middle Aged
  • Mitoxantrone / therapeutic use
  • Mutation
  • Myeloproliferative Disorders / diagnosis*
  • Myeloproliferative Disorders / genetics
  • Myeloproliferative Disorders / metabolism
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / secondary

Substances

  • Antineoplastic Agents
  • Etoposide
  • Mitoxantrone
  • Janus Kinase 2